Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ram W Sabnis

Showing results (31-40 of 251) with videos related to

Pageof 26
Sort By:
ACS Medicinal Chemistry Letters|May 14, 2025
Novel Piperidine Substituted Pyrazolopyrimidine Derivatives as SGK1 Inhibitors for Treating Cardiovascular DiseasesRam W Sabnis
ACS Medicinal Chemistry Letters|May 14, 2025
Novel Indole and Pyrrolopyridine Derivatives as GPR17 Modulators for Treating Multiple SclerosisRam W Sabnis
ACS Medicinal Chemistry Letters|August 20, 2025
Novel Compounds as 5‑HT2A Agonists for Treating DepressionRam W Sabnis
ACS Medicinal Chemistry Letters|February 18, 2026
Novel 6‑Aminopurine Derivatives as POLQ Inhibitors for Treating CancerRam W Sabnis
ACS Medicinal Chemistry Letters|February 18, 2026
Novel Compounds as MALT1 Inhibitors for Treating CancerRam W Sabnis
ACS Medicinal Chemistry Letters|June 18, 2025
Novel Isotryptamine Tetracycles as 5‑HT2A Agonists for Treating Brain DisordersRam W Sabnis
ACS Medicinal Chemistry Letters|June 18, 2025
Novel Phenylalkylamines as 5‑HT2A Agonists for Treating Psychiatric DisordersRam W Sabnis
ACS Medicinal Chemistry Letters|June 14, 2023
Novel 2,5-Diazabicyclo[4.2.0]octanes as GLP-1 Receptor Modulators for Treating Type 2 DiabetesRam W Sabnis
ACS Medicinal Chemistry Letters|March 18, 2026
Novel Pyrrolopyridazine VEGFR Tyrosine Kinase Inhibitors for Treating CancerRam W Sabnis
ACS Medicinal Chemistry Letters|February 14, 2024
Novel PARP1 Inhibitors for Treating CancerRam W Sabnis
Pageof 26

Showing results (31-40 of 251) with videos related to

Sort By:
Pageof 26
ACS Medicinal Chemistry Letters|May 14, 2025
Novel Piperidine Substituted Pyrazolopyrimidine Derivatives as SGK1 Inhibitors for Treating Cardiovascular DiseasesRam W Sabnis
ACS Medicinal Chemistry Letters|May 14, 2025
Novel Indole and Pyrrolopyridine Derivatives as GPR17 Modulators for Treating Multiple SclerosisRam W Sabnis
ACS Medicinal Chemistry Letters|August 20, 2025
Novel Compounds as 5‑HT2A Agonists for Treating DepressionRam W Sabnis
ACS Medicinal Chemistry Letters|February 18, 2026
Novel 6‑Aminopurine Derivatives as POLQ Inhibitors for Treating CancerRam W Sabnis
ACS Medicinal Chemistry Letters|February 18, 2026
Novel Compounds as MALT1 Inhibitors for Treating CancerRam W Sabnis
ACS Medicinal Chemistry Letters|June 18, 2025
Novel Isotryptamine Tetracycles as 5‑HT2A Agonists for Treating Brain DisordersRam W Sabnis
ACS Medicinal Chemistry Letters|June 18, 2025
Novel Phenylalkylamines as 5‑HT2A Agonists for Treating Psychiatric DisordersRam W Sabnis
ACS Medicinal Chemistry Letters|June 14, 2023
Novel 2,5-Diazabicyclo[4.2.0]octanes as GLP-1 Receptor Modulators for Treating Type 2 DiabetesRam W Sabnis
ACS Medicinal Chemistry Letters|March 18, 2026
Novel Pyrrolopyridazine VEGFR Tyrosine Kinase Inhibitors for Treating CancerRam W Sabnis
ACS Medicinal Chemistry Letters|February 14, 2024
Novel PARP1 Inhibitors for Treating CancerRam W Sabnis
Pageof 26